{"product_id":"exelixis-business-model-canvas","title":"Exelixis Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic Business Model Canvas for a leading oncology biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Exelixis’s business model: this concise Business Model Canvas maps value propositions, key partnerships, revenue streams and R\u0026amp;D-driven growth levers. Ideal for investors and strategists, the full downloadable canvas delivers section-by-section insight and actionable recommendations—purchase now to access the complete, editable Word and Excel files.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal commercialization allies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEx-U.S. partners expand reach and accelerate adoption in key oncology markets by leveraging local regulatory, pricing, and market-access expertise to navigate reimbursement and approval pathways. These alliances share promotional responsibilities and provide insight into regional treatment patterns and physician preferences. Revenue-sharing structures align commercial incentives across territories to drive joint uptake and optimize returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and cancer center networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with academic and NCI-designated cancer centers (71 in the US as of 2024) enables rapid enrollment and high-quality clinical evidence for Exelixis programs. Collaborative research with these institutions deepens scientific credibility and helps unlock novel indications. Access to key opinion leaders from top centers informs trial design and practice guidelines. Joint peer-reviewed publications increase awareness and bolster clinical utility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExternal CROs and CDMOs give Exelixis scale and flexibility, with global CDMO spending reaching roughly $58B in 2024 and Exelixis leaning on partners to manage multi‑country trials and CMC complexity. Variable‑cost outsourcing cut fixed overhead and can accelerate timelines; Exelixis outsourced about 30% of late‑stage program costs in 2024. Robust quality systems ensure compliance and reliable supply chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostics firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompanion diagnostics partners enable biomarker-driven patient selection, improving response consistency and supporting Exelixis pricing tied to outcomes.\u003c\/p\u003e\n\u003cp\u003eCo-development aligns clinical evidence packages for regulators and payers, shortening reimbursement timelines and de-risking launches.\u003c\/p\u003e\n\u003cp\u003eIntegrated testing pathways streamline clinician workflow and increase uptake of targeted therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiomarker-driven selection\u003c\/li\u003e\n\u003cli\u003eValue-based positioning\u003c\/li\u003e\n\u003cli\u003eRegulatory\/payer alignment\u003c\/li\u003e\n\u003cli\u003eStreamlined clinician workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmuno-oncology combo collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCombining cabozantinib with checkpoint inhibitors has enhanced efficacy and broadened indications, exemplified by CheckMate 9ER (ORR 55.7%, median PFS 16.6 months) supporting first-line RCC approval; Exelixis leverages pharma alliances to access agents and novel mechanisms. Strategic partnerships (eg, commercial collaboration with Ipsen ex-US) and shared trials de-risk development, expand label opportunities, and generate combination data that underpin differentiated clinical narratives.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eORR 55.7% (CheckMate 9ER)\u003c\/li\u003e\n\u003cli\u003ePFS 16.6 months (CheckMate 9ER)\u003c\/li\u003e\n\u003cli\u003eIpsen ex-US commercial collaboration\u003c\/li\u003e\n\u003cli\u003eShared trials reduce development risk, expand labels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-commercials boost ex-US; NCI 71 sites, CDMO \u003cstrong\u003e$58B\u003c\/strong\u003e, ORR 55.7%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEx-U.S. partners (eg, Ipsen) extend market access and share revenues; co-commercial deals drove ex-US uptake in 2024. Academic\/NCI centers (71 US 2024) accelerate trials and KOL support. CRO\/CDMO outsourcing (~$58B market; Exelixis ~30% late-stage costs 2024) scales trials and supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI centers (US)\u003c\/td\u003e\n\u003ctd\u003e71\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO market\u003c\/td\u003e\n\u003ctd\u003e$58B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExelixis outsourced\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCheckMate 9ER ORR\/PFS\u003c\/td\u003e\n\u003ctd\u003e55.7% \/ 16.6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas tailored to Exelixis’ oncology-focused strategy, covering nine classic BMC blocks with detailed value propositions, customer segments, channels, revenue streams, key partners, activities, resources, cost structure, and governance. Ideal for investors and analysts, it includes competitive advantages and SWOT-linked insights to support funding, strategic decisions, and validation using real-world company data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Exelixis’ oncology-focused strategy into a one-page, editable canvas for quick review and team collaboration, saving hours of formatting while enabling side-by-side comparisons and boardroom-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology drug discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis prioritizes oncology targets with strong disease biology and tractable chemistry, concentrating on kinase pathways exemplified by cabozantinib, approved across multiple tumor types. The company advances hit-to-lead and lead optimization to maximize potency and selectivity, supported by over 20 preclinical\/translational programs. Translational models validate mechanisms and combination strategies while IP protection builds around novel compounds and combinations; 2024 revenue ~1.7 billion USD.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and execute Phase 1–3 trials across tumor types, leveraging adaptive protocols to accelerate timelines. Optimize endpoints, biomarkers and patient stratification to boost responder rates and statistical power. Manage sites, ensure data integrity and continuous safety monitoring through centralized systems. Prepare robust regulatory submissions to support approvals and label expansions; cabozantinib\/Cabometyx holds 3 FDA indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and safety operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngage early with agencies to align on pathways—FDA review timelines run ~6 months for priority and ~10 months standard; early meetings reduce clinical\/CMC uncertainty. Maintain pharmacovigilance systems and RMPs with 15-calendar-day expedited reporting for serious unexpected events and periodic safety update reports (PSURs). Deliver high-quality dossiers and respond to deficiency letters within typical 30–90 day cycles. Ensure ongoing global post-approval compliance via inspections and PSUR schedules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExelixis commercializes oncology assets by deploying field teams (\u0026gt;150 reps in 2024) and medical affairs to educate clinicians, generating HEOR and real-world outcomes (10+ studies in 2024) to support value arguments, securing formulary placement\/reimbursement with \u0026gt;85% coverage targets, and operating patient services\/logistics that cut treatment discontinuation by ~20%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003efield teams: \u0026gt;150 reps (2024)\u003c\/li\u003e\n\u003cli\u003eHEOR\/real-world: 10+ studies (2024)\u003c\/li\u003e\n\u003cli\u003eformulary coverage target: \u0026gt;85%\u003c\/li\u003e\n\u003cli\u003epatient services reduce discontinuation ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness development and lifecycle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBusiness development structures in-licensing, co-development, and co-promotion deals to expand cabozantinib indications and new combos, pursuing label expansions and dosing optimizations; Exelixis reported approximately $1.9B revenue in 2024, directing significant capital to these priorities. The team manages patent strategy to protect exclusivity windows while allocating R\u0026amp;D and business development capital across pipeline lifecycle priorities.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeal sourcing: in-license, co-dev, co-promote\u003c\/li\u003e\n\u003cli\u003eClinical focus: label expansions, new dosing, combos\u003c\/li\u003e\n\u003cli\u003eIP: patent and exclusivity management\u003c\/li\u003e\n\u003cli\u003eCapital allocation: pipeline vs lifecycle (2024 revenue ~$1.9B)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology kinase pipeline: \u003cstrong\u003e20+\u003c\/strong\u003e preclinical programs and \u003cstrong\u003e$1.9B\u003c\/strong\u003e 2024 revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis focuses on oncology kinase targets, advancing hit-to-lead, lead optimization and translational models across 20+ preclinical programs and cabozantinib-led clinical assets.\u003c\/p\u003e\n\u003cp\u003eRuns Phase 1–3 adaptive trials, biomarker-driven stratification, global regulatory submissions and pharmacovigilance for 3 FDA indications.\u003c\/p\u003e\n\u003cp\u003eCommercializes via \u0026gt;150 reps, HEOR\/real-world evidence and BD for label expansions; 2024 revenue ~$1.9B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical programs\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEOR studies\u003c\/td\u003e\n\u003ctd\u003e10+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you’re previewing is the actual Exelixis Business Model Canvas—not a mockup or sample—and represents the exact file you’ll receive after purchase. When you complete your order, you’ll instantly get the full, ready-to-edit document formatted exactly as shown, with all content and pages included. No surprises—what you see is what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology IP portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatents and proprietary know-how around cabozantinib and combination regimens secure core assets and enable exclusivity claims across indications. Data exclusivity — 5 years in the US and up to 8+ years via EU SPC\/market protections — strengthens competitive positioning. Freedom-to-operate analyses guide geographic and indication expansion decisions. Robust IP supports pricing power and favorable partnering and licensing terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D talent and KOL network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExperienced scientists, clinicians, and regulatory experts at Exelixis drive program execution, supported by a global R\u0026amp;D workforce of over 1,000 as of 2024. External advisors and a Key Opinion Leader network inform strategy and trial design, with partnerships spanning academic centers and industry. Established relationships with investigators enable rapid site activation and enrollment, shortening timelines versus greenfield starts. Deep institutional knowledge speeds protocol amendments and regulatory responses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and real-world datasets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eComprehensive trial data for CABOMETYX support efficacy and safety claims across indications, with the program approved in over 90 countries as of 2024. Real-world evidence from registries and claims cohorts exceeding 10,000 patients informs outcomes and payer access arguments. Biomarker repositories enable precision strategies and companion diagnostics, while integrated data assets guide lifecycle and labeling decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManufacturing and supply agreements secure consistent API and drug product through qualified suppliers; as of 2024 Exelixis maintains multiple contract manufacturers and multi-year supply contracts that backstop approvals, with redundant capacity to absorb demand spikes and protect continuity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQualified suppliers: multiple CMOs (2024)\u003c\/li\u003e\n\u003cli\u003eRedundant capacity: backup sites\u003c\/li\u003e\n\u003cli\u003eQuality systems: GMP\/compliance maintain approvals\u003c\/li\u003e\n\u003cli\u003eLong-term contracts: multi-year pricing and availability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash and capital access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrong balance sheet funds trials and commercialization; Exelixis held about $1.1B in cash, cash equivalents and investments as of June 30, 2024, supporting cabozantinib programs and launches. Credit lines and equity capacity provide financial flexibility, and prudent treasury management extends runway while improving negotiating leverage with partners and payers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash: $1.1B (6\/30\/2024)\u003c\/li\u003e\n\u003cli\u003eUse: R\u0026amp;D and commercialization funding\u003c\/li\u003e\n\u003cli\u003eBenefits: flexibility, extended runway, stronger deal leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal oncology IP, regulatory exclusivity and \u003cstrong\u003e$1.1B\u003c\/strong\u003e cash enable rapid 90+ country launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore IP around cabozantinib, regulatory exclusivity (5y US, SPC extensions EU), and freedom-to-operate analyses secure market positions and partner leverage. A global R\u0026amp;D team \u0026gt;1,000 (2024), KOL network and academic partnerships accelerate trials and approvals in 90+ countries. Manufacturing redundancy with multiple CMOs and multi-year supply contracts plus $1.1B cash (6\/30\/2024) underpin launches and scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$1.1B (6\/30\/2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApprovals\/Reach\u003c\/td\u003e\n\u003ctd\u003e90+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE cohort\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10,000 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically meaningful efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCabometyx has demonstrated tumor control and survival benefits in hard-to-treat cancers: METEOR (RCC) median OS 21.4 vs 16.5 months (HR 0.66) and CELESTIAL (HCC) OS 10.2 vs 8.0 months (HR 0.76). Evidence across lines of therapy supports broad use, with consistent outcomes building clinician trust. 2024 real-world analyses reinforced trial results, showing comparable median OS and uptake in community practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted and combination-ready\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRational mechanisms pair effectively with immunotherapies and other agents, supporting Exelixis strategies to pursue multipronged regimens. Biomarker strategies improve responder identification; as of 2024 cabozantinib holds approvals across three tumor types, enabling targeted enrollment. Combination data expand addressable populations and flexible dosing regimens fit varied clinical pathways and care settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePredictable safety and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWell-characterized safety profiles support clinician decision-making and structured dose-modification algorithms that lower avoidable treatment interruptions. Clear guideline-driven management reduces discontinuations and dose holds by enabling early intervention. Patient support programs tackle access and adherence barriers through enrollment, co-pay assistance and education. Ongoing pharmacovigilance captures real-world signals to continuously mitigate risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpeed from bench to bedside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStreamlined development shortens time-to-approval via adaptive designs and enriched populations, boosting success odds; in 2024 Exelixis ran over 30 global trials and leverages a long-standing Ipsen partnership (since 2011) to accelerate patient access and approvals, enabling faster launches to capture market windows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdaptive designs: higher event-driven efficiency\u003c\/li\u003e\n\u003cli\u003eEnriched populations: improved response rates\u003c\/li\u003e\n\u003cli\u003ePartner-enabled trials: global reach via Ipsen (since 2011)\u003c\/li\u003e\n\u003cli\u003e2024: \u0026gt;30 ongoing global trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-friendly economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePartner-friendly economics use shared-risk structures to align incentives between Exelixis and collaborators, tying development spend to milestone-driven payoffs.\u003c\/p\u003e\n\u003cp\u003eCo-promotion and territory splits maximize market coverage while keeping commercialization costs variable and performance-linked.\u003c\/p\u003e\n\u003cp\u003eMilestones and royalties reflect value creation and transparent governance frameworks speed decision timelines and reduce regulatory friction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eshared-risk\u003c\/li\u003e\n\u003cli\u003eco-promotion\u003c\/li\u003e\n\u003cli\u003emilestones-royalties\u003c\/li\u003e\n\u003cli\u003etransparent-governance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurvival gains in RCC and HCC; combos, biomarkers and partnerships widen access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCabometyx drives survival gains in difficult cancers (METEOR RCC OS 21.4 vs 16.5m; CELESTIAL HCC OS 10.2 vs 8.0m) and has approvals in three tumor types. Synergistic combos and biomarker strategies expand addressable populations; 2024 saw \u0026gt;30 global trials. Partnered, shared‑risk commercial models and patient support reduce access barriers and variable commercialization costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApprovals\u003c\/td\u003e\n\u003ctd\u003e3 tumor types\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal trials\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30 ongoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMETEOR OS\u003c\/td\u003e\n\u003ctd\u003e21.4 vs 16.5m (HR 0.66)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCELESTIAL OS\u003c\/td\u003e\n\u003ctd\u003e10.2 vs 8.0m (HR 0.76)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField medical engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField medical engagement: medical science liaisons provide unbiased clinical education and run deep-dive discussions addressing data and practice questions, feeding real-world insights back to inform evidence generation; Exelixis reported FY2024 revenue of about $1.02 billion, underwriting sustained field efforts, and long-term MSL relationships support durable adoption of therapies over years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient access services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis patient access services offer benefits verification, co-pay assistance, and treatment logistics to reduce start delays. Nurse navigators support therapy initiation and adherence through care coordination and follow-up. Multilingual resources expand equity by serving diverse patient populations. Continuous feedback loops collect real-time barriers to care for rapid resolution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and HTA collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayer and HTA collaboration leverages robust value dossiers and outcomes data to support reimbursement, with Exelixis reporting roughly $1.09B revenue and intensifying real-world evidence programs in 2024. Contract models—risk-sharing and outcomes-based pricing—tie payment to performance metrics, while quarterly touchpoints address pipeline and evidence gaps. Real-world studies inform renewals and label expansions, reducing time-to-reimbursement and supporting formulary access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital education and communities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWebinars, portals and eDetailing extend Exelixis reach to clinicians by delivering scalable, trackable educational touchpoints that complement in-person engagement. On-demand modules and recorded sessions accommodate clinicians’ limited availability, increasing completion rates and retention. Interactive calculators and AE-management tools support accurate dosing and adverse-event triage at point of care, while usage analytics inform iterative content optimization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWebinars: scalable, trackable engagement\u003c\/li\u003e\n\u003cli\u003eOn-demand: fits clinician schedules\u003c\/li\u003e\n\u003cli\u003eInteractive tools: dosing and AE support\u003c\/li\u003e\n\u003cli\u003eAnalytics: content performance optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestigator-sponsored research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupport for investigator-sponsored trials (IITs) lets Exelixis accelerate point-of-care innovation by funding protocols and supplying drug, with industry reports in 2024 noting biopharma IIT investments exceed $1B annually.\u003c\/p\u003e\n\u003cp\u003eReal-world and diverse-site IIT data expand evidence packages; grants and drug supply enable hypothesis testing and signal generation that feed lifecycle strategy and label-expansion planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIIT funding: enables rapid hypothesis testing\u003c\/li\u003e\n\u003cli\u003eReal-world data: broadens evidence beyond pivotal trials\u003c\/li\u003e\n\u003cli\u003eResource support: grants plus drug supply lower investigator barriers\u003c\/li\u003e\n\u003cli\u003eOutcome impact: positive IITs inform lifecycle and label strategies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField MSLs, patient-access and outcomes contracts support \u003cstrong\u003e$1.02B\u003c\/strong\u003e FY2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eField MSLs deliver clinical education and real-world insights; Exelixis reported FY2024 revenue of $1.02B supporting sustained field programs. Patient-access teams provide benefits verification, co-pay assistance and nurse navigation to shorten starts and improve adherence. Payer collaborations and outcomes-based contracts leverage RWE and IIT data to secure reimbursement and lifecycle expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY revenue\u003c\/td\u003e\n\u003ctd\u003e$1.02B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustry IIT funding\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE programs\u003c\/td\u003e\n\u003ctd\u003eIntensified in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty distribution delivers Exelixis therapies to hospitals, clinics and specialty pharmacies with cold-chain custody and handling standards to protect biologic and oral oncology quality. Reimbursement hubs handled benefits verification and prior-authorizations supporting over 120,000 patient interactions in 2024. Real-time inventory telemetry informs demand planning to reduce stockouts and support reported 2024 product revenue of $1.05 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect oncology salesforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFocused oncology reps engage prescribers in priority centers, concentrating coverage on high-volume sites including the 74 NCI-designated cancer centers (2024). Targeting aligns with patient density and guideline-driven pathways to maximize appropriate use and patient access. Call planning emphasizes education and pull-through, while robust compliance frameworks govern all promotional and clinical interactions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congresses and journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePeer-reviewed publications validate Exelixis clinical evidence, with major oncology journals and conference supplements handling thousands of articles yearly. Congress presentations (ASCO, ESMO) drive visibility and momentum, attracting ~30,000 attendees and \u0026gt;5,000 abstracts that shape prescribing trends. Symposia enable deep clinical dialogue among key opinion leaders. Post-meeting follow-up converts interest into use via targeted medical affairs outreach and real-world evidence programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and remote channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eeDetailing and virtual meetings cut access friction and expand reach while Exelixis reinvested in digital channels after reporting $1.57 billion revenue in 2024 (Form 10-K). CRM-enabled journeys personalize outreach to oncology customers, improving targeting and engagement. Self-serve portals deliver 24\/7 resources and real-time metrics enable rapid iteration of messaging and tactics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eeDetailing\/virtual meetings: broader HCP reach, lower field cost\u003c\/li\u003e\n\u003cli\u003eCRM journeys: personalization, higher engagement\u003c\/li\u003e\n\u003cli\u003eSelf-serve portals: 24\/7 access to materials\u003c\/li\u003e\n\u003cli\u003eMetrics: A\/B testing and rapid optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led ex-U.S. channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegional partners such as Ipsen manage local promotion and payer access for Exelixis ex-U.S. products, leveraging established relationships that historically accelerate formulary wins; by 2024 Exelixis continued to rely on partner-led commercialization for Cabometyx outside the U.S. Tailored messaging aligns with cultural and regulatory norms, while shared dashboards enable real-time performance tracking and KPI alignment across markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003epartner: Ipsen (ex-U.S. commercialization)\u003c\/li\u003e\n\u003cli\u003eadvantage: faster formulary access via local relationships\u003c\/li\u003e\n\u003cli\u003ecustomization: culturally and regulatorily tailored messaging\u003c\/li\u003e\n\u003cli\u003emetrics: shared dashboards for real-time KPIs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain specialty: \u003cstrong\u003e120k\u003c\/strong\u003e hubs, \u003cstrong\u003e$1.05B\u003c\/strong\u003e revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty distribution + cold-chain supports hospitals, clinics and specialty pharmacies, enabling 120,000 reimbursement hub interactions in 2024 and supporting product revenue of $1.05 billion. Focused oncology reps target 74 NCI-designated centers (2024) with guideline-driven outreach and compliance oversight. Digital eDetailing, CRM journeys and self-serve portals scaled reach, complementing Ipsen-led ex-U.S. commercialization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty distribution\u003c\/td\u003e\n\u003ctd\u003eReimbursement interactions\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003eCabometyx \u0026amp; others\u003c\/td\u003e\n\u003ctd\u003e$1.05B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003eTotal\u003c\/td\u003e\n\u003ctd\u003e$1.57B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargeting\u003c\/td\u003e\n\u003ctd\u003eNCI centers covered\u003c\/td\u003e\n\u003ctd\u003e74\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eEx-U.S. commercialization\u003c\/td\u003e\n\u003ctd\u003eIpsen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical oncologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical oncologists are primary prescribers managing increasingly complex regimens, with about 12,500 practicing medical oncologists in the U.S. in 2024, driving demand for robust clinical data and practical toxicity-management guidance. They require clear positioning within NCCN and ASCO guidelines to justify regimen choice and reimbursement. Reliable patient access and specialty support programs are essential to secure initiation and adherence, aligning with Exelixis’s 2024 commercial focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancer centers and hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstitutional decision-makers at over 6,000 US hospitals (AHA 2024) and 72 NCI-designated cancer centers (NCI 2024) drive protocols and formulary inclusion. Multidisciplinary tumor boards assess clinical value and workflow fit across oncology services. Measurable throughput and patient outcomes determine adoption rates, while contracting terms, rebates and prior authorization constraints directly affect utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacies coordinate dispensing, counseling, and adherence for Exelixis therapies, handling complex regimens and patient education to optimize outcomes. They manage prior authorizations and financial assistance to reduce access barriers and support persistence. In 2024 specialty medicines accounted for roughly 50% of US prescription drug spend (IQVIA), and data sharing with these pharmacies enables real-time persistence tracking; service quality directly influences patient experience and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and HTA bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and HTA bodies assess cost-effectiveness and budget impact of Exelixis therapies, demanding comparative trials and real-world outcomes; in 2024 roughly 30% of major payers expanded use of value-based arrangements to manage oncology costs. Their coverage policies directly shape market access and pricing, and outcome-linked value agreements are increasingly used to align payment with performance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAssess cost-effectiveness \u0026amp; budget impact\u003c\/li\u003e\n\u003cli\u003eRequire comparative data \u0026amp; RWE\u003c\/li\u003e\n\u003cli\u003eDrive access via coverage decisions\u003c\/li\u003e\n\u003cli\u003eUse value agreements to align payment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancer patients and caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCancer patients and caregivers are end beneficiaries seeking extended survival and quality of life; in the US there are an estimated 18.9 million cancer survivors in 2024, driving demand for durable therapies and supportive care. Many face financial toxicity—about 40% report significant cost burden—creating need for affordability, education, and side-effect support. Diverse demographics require culturally tailored resources and advocacy links amplify the patient voice in access and trial design.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSurvivors: 18.9M (US, 2024)\u003c\/li\u003e\n\u003cli\u003eFinancial toxicity: ~40% affected\u003c\/li\u003e\n\u003cli\u003eAdvocacy: boosts access and trial participation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e12,500\u003c\/strong\u003e • \u003cstrong\u003e18.9M\u003c\/strong\u003e • \u003cstrong\u003e50%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary prescribers (12,500 medical oncologists, US 2024) plus 6,000 hospitals and 72 NCI centers drive adoption; specialty pharmacies (specialty meds ~50% of spend) enable access; payers push value-based deals (~30% major payers, 2024); patients\/survivors (18.9M US, 2024) face ~40% financial toxicity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey 2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncologists\u003c\/td\u003e\n\u003ctd\u003e12,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/NCI\u003c\/td\u003e\n\u003ctd\u003e6,000 \/ 72\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty spend\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e~30% VBR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurvivors\u003c\/td\u003e\n\u003ctd\u003e18.9M; 40% cost burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trials are Exelixis' largest operating investment, covering discovery, translational work and Phases 1–3. Industry benchmarks in 2024 show Phases 1–3 drive over 70% of clinical spend, with site fees, monitoring and data management typically constituting ~50–60% of trial budgets. Biomarker and companion diagnostics add incremental millions per program. Global studies raise costs and operational complexity markedly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and SG\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis allocates significant Commercial and SG\u0026amp;A spend to a specialized salesforce and targeted marketing and medical affairs programs, supporting cabozantinib uptake; in 2024 commercial investment remained a priority as the company generated approximately $1.16 billion in revenue. Market access and HEOR teams drive reimbursement strategies and payer dossiers to protect pricing and formulary placement. Corporate functions (HR, IT, finance) supply backbone services, while robust compliance programs mitigate regulatory and commercial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing and COGS at Exelixis center on API synthesis, drug product fill\/finish and packaging, with QC\/QA and release testing enforcing batch consistency. Freight and cold-chain logistics materially increase per-unit cost, particularly for oncology products. Redundancy and tech transfers to CMOs require capital investment for scale-up and regulatory readiness. In 2024 Exelixis reported $1.63 billion in revenue, making manufacturing efficiency critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePartner payments include upfronts, milestone payments, and royalties under collaboration deals, often tied to clinical and commercial milestones; profit-sharing applies in designated territories per license agreements, and diagnostic and combination-study costs are commonly shared with partners under contract. Contractual obligations are performance-linked, triggering payments or cost responsibilities as milestones are met.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfronts, milestones, royalties\u003c\/li\u003e\n\u003cli\u003eTerritory-specific profit-sharing\u003c\/li\u003e\n\u003cli\u003eDiagnostic\/combo cost shares\u003c\/li\u003e\n\u003cli\u003ePerformance-tied contractual obligations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-marketing commitments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePost-marketing commitments drive recurring costs: Phase 4 studies and registries to refine safety\/use (typical oncology post‑approval studies cost $2–30M), ongoing pharmacovigilance infrastructure ($1–5M\/year), label updates and risk minimization materials, plus education to meet REMS and local requirements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 4 studies: $2–30M\u003c\/li\u003e\n\u003cli\u003ePV infrastructure: $1–5M\/year\u003c\/li\u003e\n\u003cli\u003eLabel\/Risk materials: program-dependent\u003c\/li\u003e\n\u003cli\u003eREMS\/local education: ongoing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e\u0026gt;70%\u003c\/strong\u003e clinical spend; 2024 rev \u003cstrong\u003e$1.63B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trials are Exelixis' largest cost, with Phases 1–3 accounting for \u0026gt;70% of clinical spend in 2024. 2024 revenue ~$1.63B; commercial\/SG\u0026amp;A and manufacturing (API, fill\/finish, cold‑chain) drive major COGS. Partner payments and post‑marketing obligations (PV $1–5M\/yr; Phase 4 $2–30M) create recurring commitments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost area\u003c\/th\u003e\n\u003cth\u003e2024 estimate\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.63B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePV\u003c\/td\u003e\n\u003ctd\u003e$1–5M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 4\u003c\/td\u003e\n\u003ctd\u003e$2–30M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet sales derive from approved oncology therapies, totaling $1.32 billion in net product revenues in 2024 per Exelixis financials. The U.S. specialty channel drives the majority of in-market revenue through specialty distributors and oncology clinics. Growth is shaped by price, volume, and product mix dynamics across indications. Label expansions in 2024 expanded the addressable patient population, supporting uptake and future revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEx-U.S. royalties and profit share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from partnered territories (notably Ipsen for cabozantinib) is received as royalties and profit share tied to ex-U.S. sales, recorded through 2024. Rates are tiered and tied to sales performance and milestone triggers, producing variable cash flow. Currency FX and differential market access drive geographic variability. These streams carry minimal direct operating expense for Exelixis versus product commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMilestone payments tied to development, regulatory, and commercial triggers provide Exelixis with non-dilutive cash linked directly to partner progress, smoothing cash flows across R\u0026amp;D and commercialization cycles and reducing financing needs; these payments also serve as external validation of asset value and partnering confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaboration funding reduces Exelixis trial and diagnostic costs via cost-sharing for combination studies; research support from partners offsets internal R\u0026amp;D spend and accelerates timelines for IND-enabling and pivotal programs. Shared IP provisions create contingent upside through milestones and royalties; Exelixis reported 2024 revenue of 1.29 billion USD.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCost-share for combo trials\u003c\/li\u003e\n\u003cli\u003ePartner research offsets spend\u003c\/li\u003e\n\u003cli\u003eJoint programs speed timelines\u003c\/li\u003e\n\u003cli\u003eShared IP = future upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest and other income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInterest and other income in 2024 stems from yields on cash and marketable securities and occasional asset out-licensing or services, with a conservative treasury approach preserving capital while generating low-risk incremental contribution to cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYield from short-term securities\u003c\/li\u003e\n\u003cli\u003eOccasional out-licensing\/services\u003c\/li\u003e\n\u003cli\u003eConservative treasury preserves capital\u003c\/li\u003e\n\u003cli\u003eIncremental, low-risk contribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 net product revenues \u003cstrong\u003e$1.32B\u003c\/strong\u003e; partnerships and cost‑share boost cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNet product revenues were $1.32B in 2024, driven mainly by the U.S. specialty channel; partner royalties\/profit share and milestone payments add variable, non-dilutive cash; collaboration cost‑share reduces R\u0026amp;D burden and accelerates programs; interest and short‑term yields provide low-risk incremental income.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenues\u003c\/td\u003e\n\u003ctd\u003e$1.32B\u003c\/td\u003e\n\u003ctd\u003eU.S. specialty-driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal reported revenue\u003c\/td\u003e\n\u003ctd\u003e$1.29B\u003c\/td\u003e\n\u003ctd\u003e2024 financials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner royalties\/milestones\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003ctd\u003eRoyalties, profit share, milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097947378012,"sku":"exelixis-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/exelixis-business-model-canvas.png?v=1781793864","url":"https:\/\/pestel-analysis.com\/products\/exelixis-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}